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Natural N-glycosylation involves a β-anomeric linkage connecting the sugar to one asparagine residue of
the protein. We herein report NMR- and modelling-based data on glycomimetics containing α-glycosidic
linkages. The bioactivity of α-Gal-containing glycopeptides has been documented by revealing binding to
two plant lectins, i.e. a potent β-trefoil toxin (Viscum album agglutinin) and β-sandwich lectin (Erythrina
corallodendron agglutinin), by NMR protocols. Docking provided insights into the 3D structures of the
resulting complexes. These results provide the basis to introduce α-substituted neoglycopeptides to the
toolbox of scaffold for the design of potent lectin inhibitors.
Introduction
Based on the fundamental importance of cellular glycans for
coding biological information, analysis of their interaction with
speciﬁc receptors (lectins) is of continued interest.1 Viewed from
the perspective of the design of potent lectin inhibitors, ana-
logues of glycopeptides offer the potential for afﬁnity increases
by tailoring the peptide portion as well the sugar moiety.2
Physiologically, the criteria of rigidity, planarity and linearity
make the common β-N-glycosidic linkage of GlcNAc to aspara-
gine the common acceptor for N-glycosylation in the three king-
doms of life.3 In addition, β-linkage to Glc is also known, as are
conjugation to L-rhamnose and GalNAc.4 Starting with the
analysis of nephritogenoside, a 21-amino-acid peptide with a tri-
saccharide (Glcα1,6Glcβ1,6Glcα1,N),5 attention has been drawn
to the possibility for α-linked N-glycosylation, also computation-
ally.6 In fact, it is possible to ﬁnd some glycoprotein structures
in the PDB (3RY6, 1U65, 3IYW) where the N-glycan is for-
mally attached in α-conﬁguration, however the low crystallo-
graphic resolution associated to the unusual geometry of the
sugar attached to Asn makes this conﬁguration more than suspi-
cious. Since a β-linked galactoside has been shown to maintain
lectin-binding properties,2d the pertinent question on properties
of respective α-N-linked compounds has prompted this study.
Based on initial synthetic work7 it was possible to take the next
step to address the issue of analysing binding properties of α-N-
linked glycopeptides carrying a galactose moiety.
In this report, NMR-based experiments,8 in combination with
molecular modelling and docking protocols, have been applied
to investigate the 3D solution structure of two model α-N-linked
galactosyl-peptides. To reveal afﬁnity for lectins the interaction
of glycopeptides 1 and 2 (Fig. 1) was tested with the plant toxin
Viscum album agglutinin (VAA), also known as a model for
lectin drug design,9 and the Erythrina cristagalli agglutinin
(from coral tree, ECA).10 Of note, the two lectins have different
folding (β-trefoil and β-sandwich), and their contact sites for the
Fig. 1 α-N-Glycopeptides 1 and 2.
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sugar are structurally well-deﬁned, recently also for VAA at
physiological pH.11 Experimentally, STD-NMR12 and
trNOESY13 protocols were used. Moreover, both proteins have
proven to be robust and reliable model systems for interaction
studies under the given conditions14 so that the combination of
NMR-derived data with docking to visualize 3D structures for
the glycopeptides–lectin complexes is feasible.
Results and discussion
Synthesis
The synthesis of Ac-Asn-(α-N-Gal)-NHMe 1 has previously
been reported.7 The model glycopeptide Ac-Ala-Asn-(α-N-Gal)-
Ala-NHMe 2 was synthesized in solution starting from Nα-ﬂuor-
enylmethoxycarbonyl-Nγ-tetra-O-acetyl-α-D-galactopyranosyl-L-
asparagine 3 (Scheme 1)7 by coupling with alanine t-butylester
hydrochloride, using PyBROP (bromotripyrrolidinophospho-
nium hexaﬂuorophosphate) as the coupling agent. The reaction
produced 4 in 83% yield (Scheme 1), which was subjected to
Fmoc removal in solution, using octanethiol (10 equiv.) and a
catalytic amount of DBU (0.5 equiv.). The crude product,
washed several times with cold diethylether and pentane 1 : 1,
was used without further puriﬁcation for the coupling reaction
with N-acetylalanine with HATU (O-(7-azabenzotriazol-1-yl)-N,
N,N′,N′-tetramethyluronium hexaﬂuorophosphate) to afford 5 in
65% yield over two steps. Removal of the tert-butyl ester from 5
with TFA in dichloromethane and subsequent reaction with
methylamine and PyBROP afforded 6 (54% yield over two
steps). Removal of the acetyl groups from the carbohydrate
moiety was performed with catalytic amounts of K2CO3 in
MeOH under carefully controlled pH conditions (pH 8–9) to
give 2 in 85% yield.
Conformational analysis of the free α-N-linked glycopeptides
The solution conformation of the two α-N-linked glycopeptides
1 and 2 was ﬁrst investigated by NMR spectroscopy and molecu-
lar mechanics calculations. Coupling constants and NOE data
were carefully analysed and enabled to determine the confor-
mational features of the peptide backbone in water solution
(Fig. 2 and Fig. S11 and S12 in ESI‡). The large experimental
3JNH,Hα coupling constants values along the peptide chain
strongly suggested the presence of an extended conformation for
the peptide backbone in solution. Nevertheless, the JHα,Hβ1/
JHα,Hβ2 values (5.1/6.5 Hz (for 1) and 8.1/7.3 Hz (for 2) of Asn
amino acid revealed that compound 1 somehow presents more
ﬂexibility around χ1 (Hα-Cα-Cβ-Hβ) than glycopeptide 2. The
absence of non-vicinal medium-range NOE contacts supported
the notion that glycopeptide 2 adopts, as its main conformation,
an extended form of the peptide backbone when free in solution
(Fig. 2 and 3). Inter-residual NOEs contacts between the side
chain NH of Asn amino acid (NH1 on the NMR spectra) and H3
and H5 of the galactose residue were also detected (Fig. 2 and
Fig. S13 in ESI‡), indicating that the galactose ring adopts the
usual 4C1 chair conformation and that the NH bond is buried
below the ring. The inspection of these NOE cross-peaks dis-
closed a certain degree of ﬂexibility around the glycosidic
linkage. Noteworthy, in the case of glycopeptide 2, the NOE
between NH of Asn (NH1) and H5 appears to be stronger when
compared to that observed between NH of Asn (NH1) and H3
proton (Fig. 2), evidence for a preferred orientation of this
linkage. In addition, the high value for the glycosidic coupling
constant (3JH1,NH = 8.3 Hz for 1, and 8.2 Hz for 2) denotes the
existence of a major anti-type orientation between the NH of
Asn (NH1) and H1 of the galactose. An unconstrained confor-
mational analysis of both α-N-glycopeptides was carried out
using MC/EM15 calculations with AMBER* force ﬁeld and a
GB/SA continuum water model,16 as implemented in Macro-
model.17 These calculations came up with mostly extended con-
formations of the peptide chains, despite the known tendency of
the force ﬁeld to overestimate folded conformations such as
γ-turns for small peptides.18 The same results were also obtained
from dynamic simulations of 1 and 2 performed both with
implicit (Macromodel, MC/SD,19 GB/SA water model) and
explicit water (AMBER 9,20 TIP3P water, periodic boundary
conditions). This structural feature, which is agreement with the
NMR data, may be favoured by the formation of H-bond inter-
action between the sugar and the peptide chain. Fig. 3 shows
representative low-energy conformations calculated for 2 and
highlights the intramolecular H-bonds predicted. To the best of
our knowledge, no data are available on the preferred confor-
mation of the Ala-Asn-Ala (ANA) tripeptide, whereas many
AXA tripeptides have been found to exist mostly in extended
conformation. A study published in 2004, for example, showed
that AXA tripeptides (X being valine, tryptophan, histidine, and
serine) predominantly adopt an extended β-strand conformation,
while AXA tripeptides, for which X is lysine and proline, prefer
a polyproline II-like (PPII) structure.21
In contrast, the Ala-Phe-Ala sequence was found to fold as an
inverse γ-turn in water.22 Therefore, it is not unambiguously
clear whether the extended conformation observed for 1 and 2 is
a direct consequence of peptide glycosylation. One additional
Scheme 1 Synthesis of the model glycopeptide Ac-Ala-Asn-(α-N-
Gal)-Ala-NHMe2. Reagents and conditions: (a) 1. H-Ala-OtBu·HCl,
PyBROP, iPr2NEt, CH2Cl2, 0 °C to room temperature, 83%; (b) 1. octa-
nethiol, cat. DBU, THF; 2. Ac-Ala-OH, HATU, iPr2NEt, DMF, 65%
over two steps; (c) 1. TFA, CH2Cl2; 2. NH2Me·HCl, PyBROP, iPr2NEt,
DMF, 54%; (d) cat. K2CO3, MeOH, 85%.
This journal is © The Royal Society of Chemistry 2012 Org. Biomol. Chem., 2012, 10, 5916–5923 | 5917
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experimental feature well-reproduced in the calculations is the
orientation around the glycosydic linkage, which agrees well
with the observed NOE and NH–H1 coupling constants. In con-
trast, the conformational ﬂexibility of the χ1 bond is not rep-
resented by the calculations, which predict exclusively the
existence of anti (N-Cα-Cβ-Cγ) conformations. Statistical analy-
sis of the occurrence of conformers for side chains from X-ray
structures of proteins shows that the frequency for the anti-con-
formation of Asn χ1 is similar as the one for the gauche(−) con-
formation.23 On the contrary, rotamer libraries generated by
computational simulations of short peptides in explicit water
show a large prevalence of the anti-conformation of the χ1
bond,24 a characteristic also observed in our conformational
searches.
The bound conformation of the α-N-linked glycopeptides to
galactose-speciﬁc proteins
Having performed structural analysis on the free compounds,
their ligand properties were studied for the two test lectins. Of
note, coming from different families, the vicinity of the primary
docking site for galactose is different for VAA and ECA. First,
STD-NMR data were collected for the individual glycopeptides
to establish their respective binding epitopes to the two
receptors.
Clear STD signals were detected for both glycopeptides in the
presence of both lectins (Fig. 4 and 5 and Fig. S16 in ESI‡). To
Fig. 2 2D-NOESY spectrum obtained for glycopeptide 2 in H2O–D2O 90 : 10 recorded at 500 MHz with 600 ms of mixing time and at 278 K.
Fig. 3 Representative low-energy conformations (within 2 kcal mol−1
from the global minimum) from the conformational search of 2, illustrat-
ing the extended conformation of the peptide and the H-bond inter-
actions predicted to occur between the sugar and the peptide chain.
Fig. 4 Epitope mapping obtained for glycopeptides 1 and 2 with VAA.
5918 | Org. Biomol. Chem., 2012, 10, 5916–5923 This journal is © The Royal Society of Chemistry 2012
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prove speciﬁcity, STD-based competition experiments were
carried out with both glycopeptides and the proteins, in the pres-
ence of lactose. Thus, the interference of lactose on the recog-
nition of glycopeptides by both lectins was demonstrated by
assessing the decrease of STD intensity of glycopetide’s proton
signals after addition of lactose. STD competition binding exper-
iments clearly indicated that the neoglycopeptides (1 and 2) and
lactose (chosen as “natural” ligand) indeed compete for the same
binding site (Fig. S17–S19 in ESI‡). The estimated binding
afﬁnities for 1 and 2 were 0.93 and 0.89 mM, respectively. As
can be seen in Fig. 4 and 5, the most intense signals corre-
sponded, in all cases, to the sugar moiety, highlighting the pre-
dominant role of the carbohydrate moiety as central binding
epitope to the lectins. The detailed epitope mapping of 1 and 2
was then achieved by normalizing the observed STD signal
intensities with respect to that of the highest STD response.
Reﬂecting structural differences between the lectins, some subtle
disparities in the molecular recognition features of both α-N-gly-
copeptides by VAA and ECA were detected. In particular, for
VAA, Gal H4 was the proton receiving more percentage of
saturation, followed by Gal H2 and Gal H3. In contrast, for
ECA, Gal H1 and H2 received the highest extent of saturation,
followed by Gal H3. The differences on the binding epitopes of
both α-N-glycopeptides 1 and 2 match perfectly with the respect-
ive epitope mapping obtained for the corresponding natural
ligand, in the presence of VAA and ECA, respectively. These
results demonstrate that the sugar moiety of these non-natural
glycopeptides is properly recognized by both lectins, but with
slightly different contacts.
Furthermore, for both lectins, the transfer of magnetization
was rather uniform to all Hα protons of glycopeptide 2. This
observation suggests that the peptide backbone adopts an
extended conformation in the bound state. Regarding interplay
of the peptide chain of compound 2 with the two proteins, slight
differences in the binding epitope were also recorded. The rela-
tive STD responses for Asn Hα, Hβ1 and Hβ2, as well as for
Ala Hα were signiﬁcantly higher in the presence of ECA than
with VAA (Fig. 4 and 5 and Fig. S16 in the ESI‡). Moving
beyond the STD experiments, the TR-NOESY approach was
tested. Due to the relatively small size of ECA (dimer of 28 763
Da per subunit),10c the corresponding experiments were not
completely satisfactory and will thus not be discussed. In con-
trast, for VAA as (AB)2 tetramer of 119.2 kDa in solution,
9c
strong negative NOE were observed, indicating efﬁcient recog-
nition (Fig. 6 and S20 in the ESI‡). The comparison of the
NOE-cross peak pattern of glycopeptides 1 and 2 in the free and
VAA-bound states indicated differences in the NOE intensities of
the proton pairs that deﬁne the conformation of the glycosidic
linkage (Fig. 2 and 6; Fig. S13 and S20 in the ESI‡). In the
bound state, the Gal NH–H3 NOE is now stronger than the Gal
NH–H5 NOE (NH1–H3 and NH1–H5 on the NMR spectra,
respectively), the opposite pattern to that observed when free inFig. 5 Epitope mapping obtained for glycopeptides 1 and 2 with ECA.
Fig. 6 trNOESY spectrum recorded at 600 MHz with 200 ms of mixing time of glycopeptide 2 in the presence of VAA (NaPi 20 mM, NaCl,
100 mM, pH = 7.4 at 278 K), with a glycopeptide–VAA molar ratio of 7 : 1. All cross-peaks present the same sign (negative) as the diagonal.
This journal is © The Royal Society of Chemistry 2012 Org. Biomol. Chem., 2012, 10, 5916–5923 | 5919
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solution. Thus, a conformational selection process around the
glycosidic linkage of 1 and 2 is taking place upon binding to
VAA. Fittingly, the NOE cross-peak patterns also provided
salient information on different rotational mobility around the
different regions of the molecules. The intra-residual NOESY
cross-peaks for the Gal and Asn residues were clearly negative,
while those for the Ala residues were close to zero. This obser-
vation indicates that the major contacts with lectin are provided
by the sugar and the Asn moiety, while the rest of the peptide
chain only provides transient interactions with the receptor.
Indeed, a much faster effective rotational correlation occurs for
the peptide backbone than for the sugar and Asn residues. This
result is in perfect accord with the STD-NMR data.
Molecular modelling
In order to generate a 3D model of the complex formed between
the two neoglycopeptides (1 and 2) and the lectins docking was
performed. The docking calculations were performed using
AutoDock4.2.25 The starting coordinates for the glycopeptides
were those obtained after energy minimization of the NMR-
based structure generated in the Schrödinger suite of programs.
Then, the 3D structures of 1 and 2 were docked into the binding
site of VAA (pdb code: 1PUM) and ECA (pdb code: 1GZC).
The obtained Autodock-based poses were carefully compared to
the available STD and trNOESY data, enabling to select those
which satisfactorily correlated with the NMR experimental data.
In solution, lectin functionality is attributed to the Tyr249 site at
subdomain 2γ.26 As example, Fig. 7 shows the 3D model of the
glycopeptide 2–VAA complex, highlighting the key intermolecu-
lar interactions. Indeed, they are basically identical to those
observed in the presence of lactose in X-ray crystallographic
analysis. There are hydrogen bonds involving Asp235, Asn256,
Gln238, with C–H⋯π interaction27 between the non-polar face
of galactose and Tyr249. Answering the question on relevance of
the peptide portion, no further H-bonds were observed between
the peptide backbone and the protein surface.
Obviously, this peptide is therefore less conducive to make
contacts than anomeric extensions such as an isoxazole extended
by furan or a 2-benzothiazolyl moiety.28 This 3D structure ﬁts
well with the STD and NOE data. Of note, it shows an extended
conformation for the peptide backbone. Following the same
methodology, different models were deduced for the other three
complexes (Fig. S21–S23 in the ESI‡), which show similar
interaction features (H-bonds and CH⋯π interaction) between
the glycopeptide and the lectins.
Conclusions
The structural properties of two α-N-linked glycopeptides (with
different extents of sequence length of the peptide portion) were
deﬁned. The bioactivity of the sugar unit was disclosed, and the
strategic combination of NMR and modelling protocols enabled
the deduction, in a non-ambiguous manner, of the key factors
involved in the recognition of these glycopeptides by selected
lectins. α-N-Linked neoglycopeptides warrant further studies
taking these models as scaffolds for the design of compounds to
target medically relevant lectins with extended sites that could
potentially interact with the peptide portion in similar fashion as
indicated for human galectins.1c,2d,29
Experimental section
Synthesis
General: Dichloromethane, methanol and N,N-diisopropylethyl-
amine (DIPEA) were dried with calcium hydride, N,N-dimethyl-
formamide (DMF) was dried with activated molecular sieves
(3 Å). Chemicals, including coupling agents (PyBROP and
HATU), were purchased from Sigma Aldrich. Amino acids
(H-Ala-OtBu·HCl; Ac-Ala-OH) were purchased from Bachem.
Reactions requiring anhydrous conditions were performed under
nitrogen. 1H and 13C NMR spectra were recorded at 400 MHz
with a Bruker AVANCE-400 instrument. Chemical shifts (δ) are
expressed in ppm relative to internal Me4Si as standard. Signals
are abbreviated as follows: s, singlet; br. s, broad singlet; d,
doublet; t, triplet; q, quartet; m, multiplet. Mass spectra were
recorded with a Bruker ion-trap Esquire 3000 apparatus (ESI
ionization) or a FT-ICR APEX II mass spectrometer and Xmass
4.7 Magnet software (Bruker Daltonics). Thin-layer chromato-
graphy (TLC) was carried out with precoated Merck F254 silica
gel plates. Flash chromatography was carried out with
Macherey–Nagel silica gel 60 (230–400 mesh) or with Biotage®
SNAP KP-C18-HS cartridges for reversed-phase chromato-
graphy. HPLC-MS analyses were performed with an Agilent
1100 instrument with a quaternary pump, diode array detector,
autosampler, thermostatted column holder coupled to a Bruker
ion-trap Esquire 3000 mass spectrometer equipped with ESI
ionization.
Nα-Fluorenylmethoxycarbonyl-Nγ-(2,3,4,6-tetra-O-acetyl-α-D-
galactopyranosyl)-L-asparagyl-L-alanine tert-butyl ester
(4). Compound 37 (100 mg, 0.146 mmol, 1 equiv.), H-Ala-OtBu
hydrochloride (58 mg, 0.321 mmol, 2.2 equiv.) and PyBROP
(150 mg, 0.321 mmol, 2.2 equiv.) were dissolved in dry CH2Cl2
(1.5 mL) under nitrogen at 0 °C. DIPEA (132 μL, 0.760 mmol,
Fig. 7 3D model of the interaction of glycopeptide 2 and VAA protein
deduced by combination of NMR and modelling. The H-bonds inter-
actions are depicted as green dashed lines.
5920 | Org. Biomol. Chem., 2012, 10, 5916–5923 This journal is © The Royal Society of Chemistry 2012
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5.2 equiv.) was added and the reaction mixture was stirred at
0 °C for 1 h and then at room temperature for 3 h (TLC, 8 : 2
chloroform–methanol and 4 : 6 hexane–EtOAc). The solvent was
evaporated, the residue was dissolved in EtOAc and the organic
phase was washed with 1 M HCl and saturated NaHCO3 and
then dried with sodium sulfate. The solvent was evaporated and
the crude was puriﬁed by ﬂash chromatography (4 : 6 hexane–
EtOAc) to afford 4 (99 mg) in 83% yield. [α]20D = +65.3 (c = 0.5,
MeOH). 1H NMR (400 MHz, CDCl3, 25 °C): δ = 7.76 (d, J =
7.4 Hz, 2 H, 4-H-, 5-H-Fmoc), 7.60 (d, J = 7.3 Hz, 2 H, 1-H-, 8-
H-Fmoc), 7.40 (t, J = 7.4 Hz, 2 H, 3-H-, 6-H-Fmoc), 7.36–7.30
(m, 2 H, Gal-NH-Asn, Asn-NH-Ala), 7.31 (t, J = 7.4 Hz, 2 H, 2-
H-, 7-H-Fmoc), 6.38 (br. s, 1 H, NH-Fmoc), 5.89 (dd, J1,NH =
7.6, J1,2 = 5.2 Hz, 1 H, 1-H), 5.43–5.40 (m, 1 H, 4-H), 5.38 (dd,
J2–3 = 10.9, J2,1 = 5.2 Hz, 1 H, 2-H), 5.34–5.28 (m, 1 H, 3-H),
4.54 (br. s, 1 H, α-H-Asn), 4.46–4.34 (m, 3 H, CH2-Fmoc,
α-H-Ala), 4.26–4.20 (m, 2 H, 9-H-Fmoc, 5-H), 4.16–4.00 (m, 2
H, 6-H), 2.94–2.85 (m, 1 H, β-CH2-Asn), 2.75–2.64 (m, 1 H,
β-CH2-Asn), 2.14 (s, 3 H, CH3CO), 2.02 (s, 3 H, CH3CO), 2.00
(s, 6 H, CH3CO), 1.45 (s, 3 H, OtBu), 1.37 (d, J = 7.2 Hz, 3H,
CH3-Ala) ppm.
13C NMR (100 MHz, CDCl3, 25 °C): δ =
171.6–169.7 (CO), 143.9, 143.8 (CquatFmoc), 141.5 (CquatF-
moc), 128.0 (C-2-, C-7-Fmoc), 127.3 (C-3-, C-6-Fmoc), 125.3
(C-1-, C-8-Fmoc), 120.2 (C-4-, C-5-Fmoc), 82.3 (Cquat-OtBu),
75.1 (C-1), 67.7 (CH2-Fmoc), 67.7, 67.4 (C-2, C-3, C-4), 66.2
(C-5), 61.6 (C-6), 51.6 (α-C-Asn), 49.3 (α-C-Ala), 47.3 (C-9-
Fmoc), 38.5 (β-CH2-Asn), 28.2 (CH3OtBu), 20.8 (4 × OAc),
18.2 (CH3-Ala) ppm. MS (ESI): m/z = 834.3 [M + Na]
+. FT-ICR
MS (ESI): calcd for [C40H49N3O15Na]
+ 834.30559; found
834.30448.
Nα-(L-N-Acetylalanyl)-Nγ-(2,3,4,6-tetra-O-acetyl-α-D-galacto-
pyranosyl)-L-asparagyl-L-alanine tert-butyl ester (5). Compound
4 (99 mg, 0.122 mmol, 1 equiv.) was dissolved in dry THF
(1.2 mL) under nitrogen. Octanethiol (211 μL, 1.219 mmol, 10
equiv.) and DBU (10 μL, 0.070 mmol, 0.5 equiv.) were added
sequentially and the reaction mixture was stirred for 1 h (TLC,
9 : 1 chloroform–methanol and 2 : 8 hexane–EtOAc). The
solvent was evaporated. The residue was washed thoroughly
with a mixture of cold diethyl ether and pentane (1 : 1). The
crude solid was then dissolved in dry DMF (1.5 mL) with Ac-
Ala-OH (40 mg, 0.305 mmol, 2.5 equiv.) and HATU (93 mg,
0.244 mmol, 2 equiv.) under nitrogen at 0 °C. DIPEA (75 μL,
0.427 mmol, 3.5 equiv.) was added and the reaction mixture was
stirred at 0 °C for 1 h and then at room temperature for 4 h
(TLC, 9 : 1 chloroform–methanol). The solvent was evaporated,
the residue was dissolved in EtOAc and the organic phase was
washed with 1 M HCl and saturated NaHCO3 and then dried
with sodium sulfate. The solvent was evaporated and the crude
was puriﬁed by ﬂash chromatography (95 : 5 chloroform–metha-
nol) to afford 5 (55 mg) in 65% yield. [α]20D = +57.7 (c = 1.05,
CH2Cl2).
1H NMR (400 MHz, CDCl3, 25 °C): δ = 8.28 (d, J =
8.6 Hz, 1 H, Gal-NH-Asn), 8.08 (d, J = 8.6 Hz, 1 H, Gal-
NH-Ala), 7.51 (d, J = 7.4 Hz, 1 H, NHAsn), 7.47 (d, J = 7.4 Hz,
1 H, NHAc), 6.54 (d, J = 7.4 Hz, 1 H, NHAla), 5.93 (dd, J1,NH
= 8.6, J1,2 = 5.3 Hz, 1 H, 1-H), 5.47–5.31 (m, 3 H, 4-H, 2-H, 3-
H), 4.78–4.70 (m, 1 H, α-H-Asn), 4.48–4.39 (m, 1 H,
α-H-AlaOtBu), 4.38–4.32 (m, 2 H, α-H-AcAla, 5-H), 4.14 (dd,
J6–6′ = 11.0, J6–5 = 7.3 Hz, 1 H, 6-H), 4.03 (dd, J6–6′ = 11.0,
J6′−5 = 6.1 Hz, 1 H, 6′-H), 2.81 (dd, Jgem = 15.4, Jα,β = 4.1 Hz,
1 H, β-HAsn), 2.73 (dd, Jgem = 15.4, Jα,β = 6.2 Hz, 1 H,
β-H-Asn), 2.14 (s, 3 H, CH3CO), 2.06 (s, 3 H, CH3CO), 2.04 (s,
6 H, CH3CO, NHCH3), 2.00 (s, 3 H, CH3CO), 1.45 (s, 3 H,
OtBu), 1.40 (d, J = 7.1 Hz, 3H, CH3-Ala), 1.36 (d, J = 7.2 Hz,
3H, CH3-Ala) ppm.
13C NMR (100 MHz, CDCl3, 25 °C): δ =
172.9–169.9 (CO), 82.2 (Cquat-OtBu), 75.0 (C-1), 67.9 (C-2),
67.7 (C-3, C-4), 66.6 (C-5), 61.6 (C-6), 50.0 (α-C-Asn), 50.0
(α-C-Ala), 49.4 (α-C-Ala) 38.7 (β-CH2-Asn), 28.2 (CH3OtBu),
23.1 (NHCH3), 20.9–20.8 (4 × OAc), 18.1 (CH3-Ala) ppm. MS
(ESI): m/z = 725.2 [M + Na]+. FT-ICR MS (ESI): calcd for
[C30H46N4O15Na]
+ 725.28519; found 725.28404.
Nα-(L-N-Acetylalanyl)-Nγ-(2,3,4,6-tetra-O-acetyl-α-D-galacto-
pyranosyl)-L-asparagyl-L-alanine N-methylamide (6). Com-
pound 5 (20 mg, 0.028 mmol, 1 equiv.) was dissolved in dry
CH2Cl2 (1.5 mL) under nitrogen. TFA (212 μL, 0.280 mmol,
100 equiv.) was added and the reaction mixture was stirred for
2 h (TLC, 9 : 1 chloroform–methanol). The solvent was co-
evaporated with toluene and with CH2Cl2. The crude product
was dissolved in dry DMF (500 μL) together with PyBROP
(29 mg, 0.062 mmol, 2.2 equiv.) and methylamine hydrochloride
(8 mg, 0.120 mmol, 4.2 equiv.) under nitrogen at 0 °C. DIPEA
(75 μL, 0.427 mmol, 3.5 equiv.) was added and the reaction
mixture was stirred at 0 °C for 1 h and then at room temperature
for 2 h (TLC, 9 : 1 chloroform–methanol). The solvent was
evaporated and the crude was puriﬁed by automated chromato-
graphy on a reversed-phase C-18 column (CH3CN–H2O 5 to
30% tr = 5 min) to afford 10 mg of 6 (54% over two steps).
[α]20D = +69.5 (c = 0.8, MeOH).
1H NMR (400 MHz, CD3OD,
25 °C): δ = 5.92 (d, J1,2 = 5.5 Hz, 1 H, 1-H), 5.52 (dd, J3–2 =
11.1, J3–4 = 3.5 Hz, 1 H, 3-H), 5.44 (m, 1 H, 4-H), 5.24 (dd,
J3–2 = 11.1, J2–1 = 5.5 Hz, 1 H, 2-H), 4.70 (dd, Jα,β = 7.2 Hz,
Jα,β = 5.3 Hz, 1H, α-H-Asn), 4.32–4.27 (m, 1 H, α-H-AlaOtBu),
4.24–4.11 (m, 3 H, α-H-AcAla, 5-H, 6-H), 4.05–3.99 (m, 1 H,
6-H), 2.93 (dd, Jgem = 15.5, Jα,β = 7.2 Hz, 1 H, β-HAsn), 2.73
(dd, Jgem = 15.5, Jα,β = 5.3 Hz, 1 H, β-H-Asn), 2.15 (s, 3 H,
CH3CO), 2.05 (s, 3 H, CH3CO), 2.02 (s, 6 H, CH3CO, NHCH3),
1.99 (s, 3 H, CH3CO), 1.38 (d, J = 7.2 Hz, 3H, CH3-Ala), 1.36
(d, J = 7.2 Hz, 3H, CH3-Ala) ppm.
13C NMR (100 MHz,
CDCl3, 25 °C): δ = 175.4–171.6 (CO), 75.6 (C-1), 69.9 (C-2),
69.1 (C-3, C-4), 67.9 (C-5), 62.7 (C-6), 51.5 (α-C-Asn), 51.4
(α-C-Ala), 50.9 (α-C-Ala) 38.1 (β-CH2-Asn), 26.6 (CONHCH3),
22.5 (NHCH3), 20.7–20.6 (4 × OAc), 17.9–17.6 (CH3-Ala)
ppm. MS (ESI): m/z = 682.3 [M + Na]+.
Nα-(L-N-Acetylalanyl)-Nγ-(α-D-galactopyranosyl)-L-aspara-
gyl-L-alanine N-methylamide (2). Compound 6 (10 mg,
0.015 mmol, 1 equiv.) was dissolved in dry methanol (250 μL)
and a catalytic amount of K2CO3 (0.1 equiv., pH 8–9) was
added. The reaction mixture was stirred for 1 h (TLC, 6 : 4
chloroform–methanol and 8 : 2 chloroform–methanol). IRA H+
120 was added to neutral pH. The mixture was ﬁltered and
washed with methanol. The solvent was evaporated and the com-
pound was puriﬁed by preparative HPLC (C-18 reverse phase,
100 : 0 to 60 : 40 H2O–CH3CN in 14 min; tr = 5 min) to afford 2
(6 mg) in 85% yield. [α]20D = +46.3 (c = 0.1, MeOH).
1H NMR
(400 MHz, CD3OD, 25 °C): δ = 5.58 (d, J1,2 = 5.6 Hz, 1 H,
1-H), 4.67 (t, J = 6.0 Hz, 1 H, α-H-Asn), 4.30–4.21 (m, 2 H,
This journal is © The Royal Society of Chemistry 2012 Org. Biomol. Chem., 2012, 10, 5916–5923 | 5921
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α-H-Ala), 3.98 (dd, J2,3 = 10.2 Hz, J2,1 = 5.6 Hz, 1 H, 2-H),
3.87 (d, J = 3.4 Hz, 1 H, 4-H), 3.74 (dd, J3–2 = 10.2 Hz, J3–4 =
3.4 Hz, 1 H, 3-H), 3.70–3.60 (m, 3 H, 5-H, 6-H), 2.85–2.78 (m,
2 H, β-CH2-Asn), 2.72 (s, 1 H, NHCH3), 1.98 (s, 3 H, NHAc),
1.36 (d, J = 7.3 Hz, 3H, CH3Ala), 1.33 (d, J = 7.2 Hz, 3H
CH3Ala) ppm.
13C NMR (100 MHz, CDCl3, 25 °C): δ =
175.5–172.6 (CO), 78.6 (C-1), 73.8 (C-5), 71.4 (C-3), 70.7
(C-4), 68.4 (C-2), 62.8 (C-6), 51.7 (α-C-Asn), 51.3 (α-C-Ala),
50.9 (α-C-Ala), 38.5 (β-CH2-Asn), 26.6 (NHCH3), 22.5
(CONHCH3), 17.9, 17.6 (CH3Ala) ppm. MS (ESI): m/z = 492.2
[M + H]+. FT-ICR MS (ESI): calcd for [C19H33N5O10Na]
+
514.21196; found 514.21128.
NMR spectroscopy
For the conformational analysis of the two α-N-linked glycopep-
tides in solution, the experiments were recorded in H2O–D2O
90 : 10 on a Bruker Avance 500 MHz spectrometer at 278 K.
2D-NOESY experiments were carried out with mixing times of
300 and 600 ms. The concentration of glycopeptides for the
NMR experiments was set to 10 mM. STD NMR experiments
were recorded at 298 K on a Bruker Avance 500 MHz spec-
trometer. VAA and ECA were dissolved in D2O buffer (20 mM
NaPi, 100 mM NaCl, pH = 7.4) and the ﬁnal concentration
measured by UV spectroscopy. For binding studies, a stock sol-
ution of the glycopeptides was prepared, thus the glycopeptides
were suspended in a buffer solution to a ﬁnal concentration of
40 mM. STD experiments were performed for a molar ratio of
100/1 (glycopeptides 1 or 2–protein). The ﬁnal concentration of
the protein in the NMR tube was 40 μM. A series of Gaussian-
shaped pulses of 49 ms each were applied, separated by 1 ms
delay, with a total saturation time for the protein envelope of 2 s
and a maximum B1 ﬁeld strength of 50 Hz. An off-resonance fre-
quency of δ = 100 ppm (where no proteins signals are present)
and on-resonance frequency of δ = 7.2 ppm and −1 ppm
(protein aromatic signals region) were employed. No signiﬁcant
differences on the epitope mapping were observed between the
two on-resonance frequencies. A total number of 1024 scans
were acquired and the spectra were multiplied by an exponential
line broadening function of 1 Hz prior to Fourier transformation.
All experiments were recorded with a 15 ms spin lock pulse,
which minimizes the protein background resonances. trNOESY
experiments (mixing time 200 ms) were recorded on a Bruker
Avance 600 MHz spectrometer equipped with a triple channel
cryoprobe at 278 K. These experiments were accomplished for a
molar ratio of 7 : 1 (glycopeptides 1 or 2–VAA) using a 60 μM
of lectin as ﬁnal concentration in the NMR tube. For this particu-
lar experiment, VAA and ECAwere dissolved in H2O buffer sol-
ution (20 mM NaPi, 100 mM NaCl, pH = 7.4). No purging spin-
lock period to remove the NMR signals of the macromolecule
background was employed. To properly analyse the sign change
of the NOE cross-peaks, a NOESY spectrum of each glycopep-
tide at 600 MHz was also recorded (see S14–S15 in ESI‡).
Conformation analysis and dynamic simulations
MC/EM calculations15 were performed using MacroModel 9.5.17
The AMBER* force ﬁeld with the Senderowitz–Still
parameters30 has been used. Water solvation was simulated using
GB/SA continuum solvent model.16 Extended non-bonded cut
off distances (a van der Waals cut off of 8.0 Å and an electro-
static cut-off of 20.0 Å) were used. The MC/EM procedure was
carried out applying 6000 and 10 000 steps for glycopeptides 1
and 2, respectively. Backbone (Φ–Ψ) and side chain (χ1–χ2)
dihedral angles were all varied during the simulation, along with
the pseudo-Φ anomeric torsion. Only conformers among
5.00 kcal mol−1 from the global minimum were analyzed and
clustered based on their backbone and side chain conformation.
The MC/SD dynamic simulations19 were run using the
AMBER* all-atom force ﬁeld and van der Waals and electro-
static cut-offs of 25 Å, together with a hydrogen bond cut-off of
15 Å. The same degrees of freedom of the MC/EM searches
were used. All simulations were performed at 300 K, with a
dynamic time-step of 1.5 fs and a frictional coefﬁcient of
0.1 ps−1. Runs of 5 ns for 1 and 10 ns for 2 were performed,
starting from conformations selected from the MC/EM outputs.
The acceptance ratios for glycopeptides 1 and 2 were 4.5 and
4.0, respectively. MD simulations in explicit water with periodic
boundary condition were performed using AMBER 920 with
ff99SB31 and glycam0432 force ﬁelds. TIP3P water model and a
truncated octahedron box with 12.0 Å buffer were used. An inte-
gration step of 1 fs and a cutoff of 10.0 Å were applied. Glyco-
peptides 1 and 2 were simulated at 300 K (using the Langevin
thermostat) and 1 atm for 20 ns and 50 ns, respectively, after an
equilibration time of 450 ps.
Docking calculations
The 3D geometries of each glycopeptide–lectin complex were
deduced by using AutoDock 4.2.25 The 3D coordinates of glyco-
peptides (1 and 2) were those obtained after the NMR-based
analysis of the compound in the free state. Starting from the
available coordinates for VAA and ECA in the Protein Data
Bank (pdb codes 1PUM and 1GZC, respectively), molecular
models of both proteins were constructed, using the protein prep-
aration wizard of Macromodel, as integrated in the Schrödinger
package. The pdb structures for both proteins were modiﬁed by
removing all the ions and waters of crystallization, with excep-
tion of W1120 and W1239, in the case of VAA, and W2262, in
the case of ECA. Hydrogens were then added and the structures
were minimized with the OPLS-2005 force ﬁeld,33 using the
convergence method Truncated Newton Conjugate Gradients, in
the presence of the water molecules. The existing ligands in the
binding site were ﬁxed to their crystallographic positions.
Finally, the natural ligand was removed from the binding pocket
and the structure of the proteins saved as a new pdb ﬁle.
Different torsional degrees of freedom for the glycopeptides 1
and 2 were considered as a ﬂexible ligand to facilitate the
docking process. The lectins were always considered as rigid
receptors. However, once the torsion angles around the peptide
chain (for compound 2) were optimized, only eight active tor-
sions were considered. Autodock default charges were used for
the glycopeptides and the protein receptors. In brief, grid maps
(with a grid spacing of 0.375 Å) were constructed using 54 × 54
× 54 points for the box dimensions. A total of 100 Lamarckian
genetic algorithm runs were performed using 2 × 107
5922 | Org. Biomol. Chem., 2012, 10, 5916–5923 This journal is © The Royal Society of Chemistry 2012
D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ita
 S
tu
di
 d
i M
ila
no
 o
n 
04
 Ja
nu
ar
y 
20
13
Pu
bl
ish
ed
 o
n 
01
 M
ar
ch
 2
01
2 
on
 h
ttp
://
pu
bs
.rs
c.
or
g 
| do
i:1
0.1
039
/C2
OB
071
35E
View Article Online
evaluations. The analysis of the different binding modes was per-
forming after clustering the results using a rmsd of 2.0 Å.
Finally, the Autodock-based geometries that satisfactorily corre-
lated with the NMR experimental data were further minimized
using Macromodel and analysed.
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